



## बिड दस्तावेज़ / Bid Document

### बिड विवरण/Bid Details

बिड बंद होने की तारीख/समय /Bid End Date/Time	24-02-2026 12:00:00
बिड खुलने की तारीख/समय /Bid Opening Date/Time	24-02-2026 12:30:00
बिड पेशकश वैधता (बंद होने की तारीख से)/Bid Offer Validity (From End Date)	120 (Days)
मंत्रालय/राज्य का नाम/Ministry/State Name	Ministry Of Defence
विभाग का नाम/Department Name	Department Of Defence Research & De
संगठन का नाम/Organisation Name	Defence Research And Development Or
कार्यालय का नाम/Office Name	*****
कुल मात्रा/Total Quantity	20
वस्तु श्रेणी /Item Category	Isoflurane Liquid for Inhalation (Q2)
वर्षों के अनुभव एवं टर्नओवर से एमएसई को छूट प्राप्त है / MSE Relaxation for Years Of Experience and Turnover	Yes   Complete
स्टार्टअप के लिए अनुभव के वर्षों और टर्नओवर से छूट प्रदान की गई है / Startup Relaxation for Years Of Experience and Turnover	Yes   Complete
बिड लगाने की समय सीमा स्वतः नहीं बढ़ाने के लिए आवश्यक बिड की संख्या। / Minimum number of bids required to disable automatic bid extension	3
दिनों की संख्या, जिनके लिए बिड लगाने की समय-सीमा बढ़ाई जाएगी। / Number of days for which Bid would be auto-extended	7
ऑटो एक्सटेंशन अधिकतम कितनी बार किया जाना है। / Number of Auto Extension count	1
बिड से रिवर्स नीलामी सक्रिय किया/Bid to RA enabled	Yes
रिवर्स नीलामी योग्यता नियम/RA Qualification Rule	H1-Highest Priced Bid Elimination
बिड का प्रकार/Type of Bid	Two Packet Bid
तकनीकी मूल्यांकन के दौरान तकनीकी स्पष्टीकरण हेतु अनुमत समय /Time allowed for Technical Clarifications during technical evaluation	2 Days
निरीक्षण आवश्यक (सूचीबद्ध निरीक्षण प्राधिकरण /जेम के साथ पूर्व पंजीकृत एजेंसियों द्वारा)/Inspection Required (By Empanelled Inspection Authority / Agencies pre-registered with GeM)	No
मूल्यांकन पद्धति/Evaluation Method	Total value wise evaluation

**बिड विवरण/Bid Details**

मध्यस्थता खंड/Arbitration Clause	No
सुलह खंड/Mediation Clause	No

**ईएमडी विवरण/EMD Detail**

आवश्यकता/Required	No
-------------------	----

**ईपीबीजी विवरण /ePBG Detail**

आवश्यकता/Required	No
-------------------	----

बोली विभाजन लागू नहीं किया गया/ Bid splitting not applied.

**एमआईआई खरीद वरीयता/MII Purchase Preference**

एमआईआई खरीद वरीयता/MII Purchase Preference	No
--------------------------------------------	----

**एमएसई खरीद वरीयता/MSE Purchase Preference**

एमएसई खरीद वरीयता/MSE Purchase Preference	Yes
सूक्ष्म और लघु उद्यम मूल उपकरण निर्माताओं को खरीद में प्राथमिकता, यदि उनका मूल्य L1+X% तक की सीमा में हो / Purchase Preference to MSE OEMs available upto price within L1+X%	15
सूक्ष्म और लघु उद्यम को खरीद में प्राथमिकता के लिए बिड की मात्रा का अधिकतम प्रतिशत / Maximum Percentage of Bid quantity for MSE purchase preference	25

1. If the bidder is a Micro or Small Enterprise as per latest orders issued by Ministry of MSME, the bidder shall be relaxed from the "Experience Criteria" as defined above subject to meeting of quality and technical specifications. The bidder seeking Relaxation shall upload supporting documents to prove his eligibility for Relaxation.
2. If the bidder is a Micro or Small Enterprise (MSE) as per latest orders issued by Ministry of MSME, the bidder shall be relaxed from the "Turnover" as defined above subject to meeting of quality and technical specifications. If the bidder itself is MSE OEM the "OEM Average Turnover" criteria also subject to meeting of quality and technical specifications. The bidder seeking Relaxation shall upload supporting documents to prove his eligibility for Relaxation.
3. If the bidder is a DPIIT registered Startup, the bidder shall be relaxed from the the eligibility criteria of "Experience of quality and technical specifications. The bidder seeking Relaxation from Experience Criteria, shall upload the supporting documents to prove his eligibility for Relaxation.
4. If the bidder is a DPIIT registered Startup, the bidder shall be relaxed from the the eligibility criteria of "Bidder Turnover" as defined above subject to meeting of quality and technical specifications. If the bidder is DPIIT Registered OEM of the offered products, it would be relaxed from the "OEM Average Turnover" criteria also subject to meeting of quality and technical specifications. The bidder seeking Relaxation from Turnover shall upload supporting documents to prove his eligibility for Relaxation.
5. Purchase preference will be given to MSEs having valid Udyam Registration and whose credentials are validated in Public Procurement Policy for Micro and Small Enterprises (MSEs) Order, 2012 dated 23.03.2012 issued by Ministry of MSME. The bidder seeking Relaxation shall upload supporting documents to prove his eligibility for Relaxation. If the bidder wants to avail themselves of the Purchase Preference, they shall be eligible to purchase the product / OEM of the offered product on GeM. Traders are excluded from the purview of Public Procurement Policy for Micro and Small Enterprises.

products manufactured by some other OEM are not eligible for any purchase preference. In respect of bid for Service offered Service. Relevant documentary evidence in this regard shall be uploaded along with the bid in respect of the eligibility for purchase preference based on documentary evidence submitted, while evaluating the bid. If L-1 is not within L-1+ 15% (Selected by Buyer) of margin of purchase preference /price band defined in relevant policy, such N price and contract will be awarded for 25% (selected by Buyer) percentage of total quantity. The buyers are advised 18.05.2023 [OM No.1\\_4\\_2021\\_PPD\\_dated\\_18.05.2023](#) for compliance of Concurrent application of Public Procurement and Public Procurement (Preference to Make in India) Order, 2017. Benefits of MSE will be allowed only if seller is val and approved by Buyer after evaluation of documents submitted.

6. Reverse Auction would be conducted amongst all the technically qualified bidders except the Highest quoting bidder will not be allowed to participate in RA. However, H-1 will also be allowed to participate in RA in following cases

- If number of technically qualified bidders are only 2 or 3.
- If Buyer has chosen to split the bid amongst N sellers, and H1 bid is coming within N.
- In case Primary product of only one OEM is left in contention for participation in RA on elimination of H-1.
- If L-1 is non-MSE and H-1 is eligible MSE and H-1 price is coming within price band of 15% of Non-MSE L-1
- If L-1 is non-MII and H-1 is eligible MII and H-1 price is coming within price band of 20% of Non-MII L-1

### Isoflurane Liquid For Inhalation ( 20 pieces )

#### तकनीकी विशिष्टियाँ /Technical Specifications

\* जेम केटेगरी विशिष्टि के अनुसार / As per GeM Category Specification

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत
PRODUCT INFORMATION	Medicine Name	Isoflurane
	Dosage Form	Liquid for inhalation
PACKAGING	Type of primary packing	Bottle
	<b>Primary pack size</b>	250 ml

#### परेषिती/रिपोर्टिंग अधिकारी तथा मात्रा/Consignees/Reporting Officer and Quantity

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	मात्रा /Quar
1	*****	*****GWALIOR	20

#### Special terms and conditions-Version:2 effective from 14-11-2025 for category Isoflurane Liquid for Inh

1. The sellers are registered on GeM and exempted from the Vendor Assessment process based on the Manufacturing Drug License certified by the issuing authority. Buyers must mandatorily ask for submit regulatory documents applicable with the bid. Buyers must also check and validate the details e.g., val drug/medicine under procurement, the license issuing authority etc. at their end.
2. The Buyer shall ask the seller to submit the "Notarized Undertaking" in the mentioned below format (sc may be verified by the buyer at their end.

#### UNDERTAKING

(to be on non-judicial stamp paper of Rs 10 and not)

I, \_\_\_\_\_, s/o / d/o / w/o \_\_\_\_\_, aged about \_\_\_\_\_ resident of \_\_\_\_\_ undertake that;

1. I am the partner / proprietor / director of \_\_\_\_\_ (name of entity) and duly \_\_\_\_\_ (Name of entity)
2. We are the manufacturers of the drug/medicine \_\_\_\_\_ ("Product") and intend to offer
3. We state that the license for the Product has been granted/obtained by us as per the provisions there under as amended till date.
4. We further state that the details regarding the Product/licenses have been uploaded by us on the \_\_\_\_\_ of the Drugs and Cosmetics Rules, 1945 as amended till date. Reference no. for SUGAM portal is \_\_\_\_\_
5. We undertake that all the information provided above is true and complete in all respect. We undertake that if any information/declaration is provided by us, suitable legal action/action as per Drugs and Cosmetic there under will be initiated.

Place:

Date:

.....

*Signature, Name, Designation & Seal*

*on behalf of the Manufacturer*

3. All Provisions of Drugs and Cosmetics Act, 1940 and Rules made there under as amended till date will also be applicable to all notifications issued by *Central Drugs Standard Control Organization (CDSCO)*, Ministry of Health & Family Welfare, Government of India, Ministry of Pharmaceuticals (DOP), Ministry of Chemicals & Fertilizers time to time in this regard.
4. All provisions of Narcotic Drugs & Psychotropic Substances Act, 1985 as amended till date will also be applicable to all Substances.
5. The purchase shall be made through Bidding/RA only irrespective of the value.
6. Manufacturer shall have a valid own manufacturing license issued by the competent drug licensing authority under the Drugs Act 1940 and Rules made there under as amended till date. The Drug/medicine quoted should be clearly mentioned in the License. The valid own manufacturing license shall be submitted to the buyer at the time of bid submission.

In case of authorized resellers/distributors, it will be the legal & regulatory liability of the manufacturer or resellers/distributors are operating in compliance with all relevant laws and regulations and are properly licensed to sell the

Manufacturer shall be responsible for verifying the validity and authenticity of drug license held by their

*If revalidation of drug license has been applied for, the buyer shall be informed accordingly and the copy of the license must be submitted with a certificate that application for renewal was made within time frame as per Drugs and Cosmetics Act that has not been deleted by drug licensing authority.*

7. Bidder/Seller shall submit the valid GMP/WHO-GMP Certificate of the manufacturing site as per revised by the Concerned Drug Licensing Authority to the buyer at the time of bid submission.
8. Bidder/Seller shall submit a valid **non-Conviction** certificate for last two (2) consecutive years issued to the buyer at the time of bid submission. The certificate must have been issued within 12 months from the date of bid submission.
9. Bidder/Seller shall submit **Manufacturing & Market Standing certificate** (in India) issued by the concerned Drug Licensing Authority for 2 consecutive years for the drug/medicine quoted to the buyer at the time of bid submission. The drug/medicine name shall be highlighted.

*This would not apply to drugs, which were introduced in India less than 2 years ago. A certificate from the Drug Licensing Authority for all new drug formulations to this effect.*

10. If a company/firm has two or more separate manufacturing units at different sites / States/region, which shall be allowed to submit only one bid for all units but necessary document regarding separate manufacturing units shall be submitted. Only one bidder will be allowed to submit only one offer for one product.
11. The manufacturer shall have in house testing facilities and valid Good Laboratory Practice (GLP) Certificate issued by the concerned Drug Licensing Authority under the Drugs Act and Rules made thereunder as amended up to date issued by Central / State Drug Controller / FDA.
12. Bidder/Seller shall have Maximum Production Capacity Certificate (section wise) issued by concerned drug licensing authority for the product.
13. STP (Standard Testing Procedure) along with the required reference standards for non-Pharmacopoeia shall be submitted by the bidder/seller at the time of submission of the bid.
14. The bidder/seller shall submit complete stability data (long term stability studies and accelerated stability studies) for at least 3 batches whenever required by the buyer. For New drugs/medicines, complete stability data shall be submitted.

(If manufacturer has licensed a formula from another company and such licensed formula is used for the product, the license should be submitted along with licensing agreement.)

15. The bidder/seller should have not been blacklisted/debarred/de-registered/banned for the quoted product by Central or State Government's Drug procurement agencies at the time of submission of bid. Further, the bidder/seller should not have been subjected to product quality testing or testing by any State Government / Central Government / its Drug procurement agencies. The bidder/seller should not have been blacklisted / debarred / de-registered/banned due to quality failure, such bidder/seller or their Partner should not participate in the bid.
16. During the validity of the bid if the firm/Company is blacklisted/debarred/de-registered/banned by any State Government's Drug procurement agencies / convicted by any Court of law in India, it shall be intimated in writing document by the bidder/seller firm/ company within one month.
17. During Contract period, if the supplier is debarred/deregistered /blacklisted/ banned by any Central Government's Drug procurement agencies due to quality failure, buyer may cancel the contract and go for fresh bid as per discretion of the buyer.
18. The firm/company/ corporation and any of its director/proprietors/ partners/ Authorized signatories should not be under any legal proceedings or pending in any court of India by any department of Govt. under prevention of Corruption Act or for diversion of Government fund or any criminal conspiracy in the said matter at the time of submission of bid.
19. Bidder/seller should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred crore) in favour of the Government of India.

*They will comply with all the statutes & legislation regarding manufacturing, import, sale, and supply of drugs and cosmetics. Acts/Enactments viz., The Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Drugs and Cosmetics (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.*

*To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 to supply items/drugs "not of standard", "Grossly sub-standard" and "Spurious and adulterated drugs" as per the order of Controller of India from time to time.*

20. The price offered by the seller/bidder shall not, in any case, exceed the DPCO/NPPA controlled price or ceiling price. The seller must reduce the prices if there is any reduction in DPCO/NPPA ceiling price or price fixed by State Government.
21. Guidelines of Department of Pharmaceuticals applicable as nodal ministry for implementing the provisions of the Government of India order (PPO) 2017-revision as amended to date, related to procurement of Goods & Services in Pharmaceuticals.
22. **Fall Clause:** Provision of fall clause will not be applicable on the sale of drugs which have an expiry date beyond 31026/1/2019-Policy dated 12-9-2020.
23. **Shelf Life:** Shelf life of each quoted drugs/medicines shall be in accordance with Schedule P of Drugs and Cosmetics Act, 1940.

In case pre-dispatch inspection is not applicable, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drugs/medicines at the time of delivery to the consignee.

In case of pre-dispatch inspection, at the time when the stores are offered for inspection, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drugs/medicines.

#### 24. **Recalls**

If products are recalled because of problems with product quality or adverse reaction to the pharmaceuticals, the seller/bidder shall immediately inform the buyer, providing full details about the reason leading to the recall, and shall take steps to replace the products at their ultimate destination with a fresh batch of acceptable pharmaceuticals or withdraw and give a full refund to the buyer. The products shall not be taken off the market due to safety problems.

#### 25. **Inspection, Testing and Quality Control**

- All the batches of the drugs/medicines supplied shall be accompanied with in-house **Test Report** from the seller's own Quality Control Lab. The Test Report/Certificate of Analysis shall include:
  1. Generic name of the product
  2. Batch No.
  3. Pharmacopoeia Reference and/ or In-house method
  4. Batch quantity
  5. Date of manufacture
  6. Expiry date
  7. Date of test
  8. Description (clarity, color etc)
  9. All identity, potency, purity, sterility, pyrogen and all other test required by the specified pharmaceutical standards. Results and the limits for the individual tests should be given
  10. Conclusion
  11. Qualified Person's signature

The above-mentioned batch shall be manufactured in accordance with the applicable GMP regulations.

- Buyer will embark on stringent quality checks to ensure that drugs/medicines/goods meet requirements. Buyer reserves the right to carry necessary inspections/tests from NABL Accredited/Government

combination of or/ all following stages:

**a) At Pre-Dispatch stage**

**b) At Delivery Stage:** Inspection done once the drugs/medicines/goods reach at consignee local inventory.

**c) Post Delivery Surveillance:** The Drugs/Medicines/goods shall have the active ingredients as indicated in official compendiums or technical specifications throughout the shelf-life period of the drug may also be organized by the buyer post-delivery.

- The Buyer may engage the services of a Quality Control Agent & Quality Control Testing Laboratory. The sampling quantities shall be borne by the supplier.
- The buyer's right to inspect, test and, where necessary reject the drugs/medicines/goods after their destination shall in no way be limited or waived by reason of the goods having previously been in dispatch from the place of manufacture.
- **Inspection Methodology:** At pre-dispatch and/or delivery stage, samples of supplies in each batch shall be collected and sent to designated laboratories (NABL Accredited/Government approved laboratories).

**At post-delivery surveillance** - The samples will be collected from the warehouse of buyer/or designated Quality Control Labs in respect of supplied drugs/medicines/goods at any point during the shelf life.

*Handling and testing charges will be borne by the buyer for the above purpose.*

- In case of failure of batches during or at any stage (indicated above), the testing charges would be borne by the supplier.
- The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories. If the batch is found to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/ batches will be rejected and the cost of the batch shall be recovered from the supplier.
- **At any of testing stage,** Samples which do not meet quality requirement shall render the relevant batch declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches of drugs/medicines/goods and the cost of entire batch paid will be recovered from the supplier when the batch is found to be "Not of Standard Quality" or spurious or adulterated or misbranded.
- If any inspected or tested drugs/medicines/goods fails to conform to the specifications or fails in any other way, the supplier will be responsible to take back the rejected drugs/medicines/goods from the depots/collected fresh stock duly inspected and tested within 45 days from the date of intimation from the buyer. The buyer has the right to destroy such rejected drugs/medicines/goods if the supplier does not take back the rejected drugs/medicines/goods within the stipulated time. The buyer will arrange to destroy the "NOT OF STANDARD QUALITY ITEMS" after the expiry of the stipulated time.

Action may also be initiated by the buyer for debarring/blacklisting against the supplier for suitable reasons. The concerned State will also be informed by the buyer for initiating necessary action on the supplier if the supplier is found to be forfeited without any intimation.

The decision of the buyer or any officer authorized by buyer, as to the quality of the supplied drugs/medicines/goods shall be final.

- In case any drug/medicine is found substandard either any of testing stage or during the shelf life period, the batch shall be rejected and the cost of the batch shall be recovered from the supplier. If the same is disputed by the supplier, the batch shall be sent to Central Drug Laboratory, Kolkata, and the report of CDL will only be accepted as final and the cost of the batch shall be recovered from the supplier. The report shall be submitted within three months, from the date of communication of the disputed test report to the concerned Drug Control Authorities for getting the drugs/medicines tested, as per the guidelines issued by the Ministry of Health & Family Welfare.

The de-registration / debarment action will be taken by the buyer against the manufacturing unit if the unit is found to be substandard on account of category-A and category-B defects as per guidelines issued by the Ministry of Health & Family Welfare communicated to GeM.

- The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the drugs/medicines/goods to the buyer. In case of any complaint in the field, the B.M.R/ B.P.R for the particular batch of the product shall be submitted to the buyer. For New drugs/medicines, complete stability data of 6 months period shall be acceptable.
- The case of admixture of drugs will be treated as a violation of terms and conditions and will not be accepted.
- Statutory provisions on manufacture, distribution, storage and quality issues of drugs/medicines/goods are up to date is vested with the DCGI (CDSCO)/ MoH& FW, including its Central/ Zonal/ Regional Drug Control Authorities. The power of confiscation, sealing or prosecution with relation to drugs/medicines under the said Act is also vested with the DCGI (CDSCO). The Controller/ Drug Inspector may exercise their powers as an Inspecting Agency.

26. **Deduction, Blacklisting, and other penalties on account of Quality failure**

The suitable conditions may be added by the buyer in the bid through Additional Term & Conditions (ATC).

**27. Quality Test by Statutory Authorities:**

If any batch of any product(s) supplied by the supplier is declared "NOT OF STANDARD QUALITY", by any authority, the supplier shall inform the same immediately to the buyer so that the use of the available stock of the product with all consignee/users will be retrieved.

**28. Termination for Default**

The buyer may without prejudice to any other remedy for breach of contract, by written notice of default whole or in part If the supplier fails to promptly replace any drug/medicine/goods rejected submitted for applicable Regulatory Authority in the country of manufacture due to unacceptable quality or reports of recall.

**29. Warranty**

- Supplies must fully comply in all respect with the Technical specifications and conditions laid down Pharmacopoeia standards.
- Each supply should be accompanied with a "Warranty Certificate" duly signed by the Bidder as u

"The Supplier/Seller hereby declares that the stores as detailed below sold to the buyer under the workmanship and shall be strictly in accordance with the specifications and particulars mentioned. The stores would continue to conform to the description of and quality aforesaid for a period of specified shelf life from the date of delivery of the said stores to the buyer, have overages within and are not subject to recall by the applicable Regulatory Authority due to unacceptable quality. Notwithstanding the above, the fact that the said stores fail to conform to the description and quality decision of the buyer in that behalf is final and conclusive, the buyer will be entitled to reject the discovered not to conform to the said description and quality. Losses due to premature deterioration of potency will be made good and supplied by the firm at its own cost at consignee's site.

On such rejection, the stores will be at the seller's risk and all provisions herein contained relating to the supplier/Seller shall if so called upon to do so by the buyer in writing, replace the stores free of cost within forty five days or such further period as may be extended from time to time by the buyer at his cost. The provisions of this contract shall apply to the stores replaced from the date of the replacement thereof otherwise the provisions as may arise by reason of the breach of the conditions. Nothing herein contained shall prejudice this contract or otherwise".

Sl. No. & Date	Nomenclature & Specification	Name & Address of Manufacturing Unit	Batch No.	DOM & DOE
----------------	------------------------------	--------------------------------------	-----------	-----------

Signature name & designation

- If the supplier, having been notified, fails to replace within the period specified above, the buyer may be necessary/deemed fit by the buyer, at the suppliers' risk and expense and without prejudice against the supplier under the contract.

**30. Packaging, Labelling and Marking Requirements**

Packaging, Labelling and Marking shall be as per the provisions contained in the Drugs and Cosmetics Act and amended up-to-date, other particulars of packaging, labelling & marking, if any, prescribed by the buyer. Conditions (ATC) shall be complied with.

**31. Bar Coding**

All drugs/medicines supplied should incorporate GS1 barcodes standards at various packaging levels (primary, secondary and tertiary) and should encode the information within the barcodes as mentioned by the buyers in addition to other requirements. Details of bar-coding will be given by the buyer through Additional Terms and Conditions.

**32. Delivery Period**

- Minimum delivery period will be of 45 days from the date of issuing of the purchase order.

- The supplier should maintain the recommended temperature of the drug/medicine (wherever found that temperature has not been maintained, supply against the said order is liable to be rejected)
  - The items requiring special cold storage conditions shall be supplied with cold chain transporting manufacturing unit to the warehouses/consignee location.
33. Any specific requirements for the packaging, labelling, logograms, printing, artwork, bar coding or any other Additional Terms and Conditions (ATC) in the bid will be applicable.
34. Any other Terms and Conditions which is not included or at variance with the conditions specified in the Additional Terms and Conditions (ATC) in the bid to ensure drugs/medicines are procured from authentic quality. The above terms and conditions are in reverse order of precedence i.e., ATC shall supersede the General Terms and Conditions (GTC), whenever there are any conflicting provisions.

## क्रेता द्वारा जोड़ी गई बिड की विशेष शर्तें/**Buyer Added Bid Specific Terms and Conditions**

### 1. **Generic**

OPTION CLAUSE: The Purchaser reserves the right to increase or decrease the quantity to be ordered up to 25% of contract. The purchaser also reserves the right to increase the ordered quantity up to 25% of the contracted rates. The delivery period of quantity shall commence from the last date of original delivery or during the extended delivery period the additional time shall commence from the last date of extended delivery. (Increased quantity ÷ Original quantity) × Original delivery period (in days), subject to minimum of 30 days. If the additional time equals the original delivery period. The Purchaser may extend this calculated delivery duration by exercising the option clause. Bidders must comply with these terms.

### 2. **Buyer Added Bid Specific ATC**

Buyer Added text based ATC clauses

Firm should attach cancel cheque/bank details. Firm's are requested to provide the compliance of STC 'author

### 3. **Scope of Supply**

Scope of supply (Bid price to include all cost components) : Only supply of Goods

## अस्वीकरण/**Disclaimer**

The additional terms and conditions have been incorporated by the Buyer after approval of the Competent Authority organization is solely responsible for the impact of these clauses on the bidding process, its outcome, and consequences arising in the bidding process due to these ATCs and due to modification of technical specifications and / or terms and conditions are incorporated by the Buyer regarding following, the bid and resultant contracts shall be treated as null and void at any stage of bidding process without any notice:-

1. Definition of Class I and Class II suppliers in the bid not in line with the extant Order / Office Memorandum issued.
2. Seeking EMD submission from bidder(s), including via Additional Terms & Conditions, in contravention to extant policy.
3. Publishing Custom / BOQ bids for items for which regular GeM categories are available without any Category restriction.
4. Creating BoQ bid for single item.
5. Mentioning specific Brand or Make or Model or Manufacturer or Dealer name.
6. Mandating submission of documents in physical form as a pre-requisite to qualify bidders.
7. Floating / creation of work contracts as Custom Bids in Services.
8. Seeking sample with bid or approval of samples during bid evaluation process. (However, in bids for [attached](#) procurement policy of the buyer nodal Ministries)
9. Mandating foreign / international certifications even in case of existence of Indian Standards without specifying.
10. Seeking experience from specific organization / department / institute only or from foreign / export experience.
11. Creating bid for items from irrelevant categories.
12. Incorporating any clause against the MSME policy and Preference to Make in India Policy.
13. Reference of conditions published on any external site or reference to external documents/clauses.

